Overview

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

Exenatide twice daily has been studied in Japanese type 2 diabetes patients. A once-weekly version of exenatide is currently being evaluated. Study GWBW is the first study of exenatide once weekly in Japanese patients. This study is designed to evaluate safety and tolerability of exenatide once weekly in Japanese patients and determine whether the dose selected for US and European development is appropriate for Japanese patients with Type 2 diabetes.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Eli Lilly and Company

Treatments:

Exenatide